These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21116617)

  • 21. Heparin--a key drug in the treatment of the circulatory degenerative diseases: controlling its action with polymers.
    Szczubiałka K; Kamiński K; Zasada K; Karewicz A; Nowakowska M
    Curr Pharm Des; 2012; 18(18):2591-606. PubMed ID: 22512445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparin and its derivatives - present and future.
    Harenberg J; Casu B
    Thromb Haemost; 2009 Nov; 102(5):801-3. PubMed ID: 19888511
    [No Abstract]   [Full Text] [Related]  

  • 23. Analysis of pharmaceutical heparins and potential contaminants using (1)H-NMR and PAGE.
    Zhang Z; Li B; Suwan J; Zhang F; Wang Z; Liu H; Mulloy B; Linhardt RJ
    J Pharm Sci; 2009 Nov; 98(11):4017-26. PubMed ID: 19642166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heparin centenary - an ever-young life-saving drug.
    Torri G; Naggi A
    Int J Cardiol; 2016 Jun; 212 Suppl 1():S1-4. PubMed ID: 27264864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A quantitative PCR method to quantify ruminant DNA in porcine crude heparin.
    Concannon SP; Wimberley PB; Workman WE
    Anal Bioanal Chem; 2011 Jan; 399(2):757-62. PubMed ID: 21058016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemometric analysis of porcine, bovine and ovine heparins.
    Ouyang Y; Han X; Yu Y; Chen J; Fu L; Zhang F; Linhardt RJ; Fareed J; Hoppensteadt D; Jeske W; Kouta A; Zhang Z; Xia K
    J Pharm Biomed Anal; 2019 Feb; 164():345-352. PubMed ID: 30428408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pattern-based recognition of heparin contaminants by an array of self-assembling fluorescent receptors.
    Jagt RB; Gómez-Biagi RF; Nitz M
    Angew Chem Int Ed Engl; 2009; 48(11):1995-7. PubMed ID: 19191358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Low molecular weight heparin in venous thromboembolism. Mechanism of action, therapy and prophylaxis].
    Stammler F; Diehm C
    Dtsch Med Wochenschr; 1998 May; 123(19):604-11. PubMed ID: 9618643
    [No Abstract]   [Full Text] [Related]  

  • 29. Low-molecular-weight heparin: biochemistry, pharmacology, and concurrent drug precautions.
    Heit JA
    Reg Anesth Pain Med; 1998; 23(6 Suppl 2):135-9. PubMed ID: 9845385
    [No Abstract]   [Full Text] [Related]  

  • 30. Lessons learned from the contamination of heparin.
    Liu H; Zhang Z; Linhardt RJ
    Nat Prod Rep; 2009 Mar; 26(3):313-21. PubMed ID: 19240943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Covalent antithrombin-heparin complexes.
    Patel S; Berry LR; Chan AK
    Thromb Res; 2007; 120(2):151-60. PubMed ID: 16978685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of impurities in heparin by capillary electrophoresis using high molarity phosphate buffers.
    Wielgos T; Havel K; Ivanova N; Weinberger R
    J Pharm Biomed Anal; 2009 Feb; 49(2):319-26. PubMed ID: 19155153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. J. Erik Jorpes--pioneer in the identification and clinical applications of heparin.
    Shampo MA; Kyle RA
    Mayo Clin Proc; 1997 Nov; 72(11):1056. PubMed ID: 9374981
    [No Abstract]   [Full Text] [Related]  

  • 34. Orthogonal analytical approaches to detect potential contaminants in heparin.
    Guerrini M; Zhang Z; Shriver Z; Naggi A; Masuko S; Langer R; Casu B; Linhardt RJ; Torri G; Sasisekharan R
    Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16956-61. PubMed ID: 19805108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
    Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
    Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simple fluorescence assay for quantification of OSCS in heparin.
    Lühn S; Schiemann S; Alban S
    Anal Bioanal Chem; 2011 Jan; 399(2):673-80. PubMed ID: 20552175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The tainted heparin story: an update.
    Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
    Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low molecular weight heparins: are they interchangeable? No.
    Nenci GG
    J Thromb Haemost; 2003 Jan; 1(1):12-3. PubMed ID: 12871532
    [No Abstract]   [Full Text] [Related]  

  • 39. Crude Heparin Preparations Unveil the Presence of Structurally Diverse Oversulfated Contaminants.
    Mendes A; Meneghetti MCZ; Palladino MV; Justo GZ; Sassaki GL; Fareed J; Lima MA; Nader HB
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31426507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Species-specific identification of ruminant components contaminating industrial crude porcine heparin using real-time fluorescent qualitative and quantitative PCR.
    Huang Q; Xu T; Wang GY; Huang JF; Xia H; Yin R; Tang A; Fu WL
    Anal Bioanal Chem; 2012 Feb; 402(4):1625-34. PubMed ID: 22147273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.